Phase II trial in head and neck squamous-cell carcinoma: adding magrolimab to pembrolizumab plus chemotherapy gave no benefit in untreated disease (median PFS 5.5 vs 5.6 months; HR 1.31); ORR 12.2% with magrolimab-docetaxel when pretreated. Closed early.
RCT
Colevas et al. Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma